ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY
Clinical trials for ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY trials appear
Sign up with your email to follow new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New 'Off-the-Shelf' cell therapy trial offers hope for kids with tough leukemia
Disease control Recruiting nowThis is a first-in-human study to test the safety and find the right dose of a new type of CAR T-cell therapy for children and young adults (up to age 21) whose CD19-positive leukemia has come back or hasn't responded to other treatments. The therapy uses immune cells (T-cells) f…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for leukemia patients: On-Site cell therapy trial opens
Disease control Recruiting nowThis study is testing whether a new type of CAR-T cell therapy can be successfully made at the hospital for patients with a specific type of leukemia that has come back or hasn't responded to other treatments. The main goal is to see if the process of creating this personalized c…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY
Phase: NA • Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
New 'Living Drug' trial offers hope for patients with aggressive blood cancers
Disease control Recruiting nowThis early-stage trial is testing the safety and best dose of a new type of personalized cell therapy called MB-CART19.1. It is for adults and children (ages 2-70) with certain B-cell blood cancers that have come back or have not responded to standard treatments. Doctors will col…
Matched conditions: ACUTE LYMPHOBLASTIC LEUKEMIA, REFRACTORY
Phase: PHASE1 • Sponsor: Nelson Hamerschlak • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC